⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10942864 | 0.97 | — | — | |
| Butane SCHEMBL10785306 | 0.90 | PAM (0.36) | — | |
| SCHEMBL347044 | 0.79 | TSHR (0.43) | — | |
| SCHEMBL7889549 | 0.74 | — | — | |
| SCHEMBL11171976 | 0.74 | — | — | |
| SCHEMBL28596528 | 0.74 | — | — | |
| SCHEMBL3360711 | 0.74 | — | — | |
| SCHEMBL3073339 | 0.72 | — | — | |
| SCHEMBL8623831 | 0.72 | — | — | |
| SCHEMBL10942913 | 0.72 | TSHR (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250137160-A1 | ANODIZED ENCLOSURE WITH FINGERPRINT RESISTANT SEALING TECHNOLOGY | APPLE INC. | 2025-05-01 | — | — | US | claimed |
| CN-101951921-A | Be used for the treatment of cachectic ways and means | BIONERIS AB | 2011-01-19 | — | — | CN | claimed |
| US-20250137160-A1 | ANODIZED ENCLOSURE WITH FINGERPRINT RESISTANT SEALING TECHNOLOGY | APPLE INC. | 2025-05-01 | — | — | US | disclosed |
| CN-101951921-A | Be used for the treatment of cachectic ways and means | BIONERIS AB | 2011-01-19 | — | — | CN | disclosed |
| CN-101164618-A | A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes | METABASIS THERAPEUTICS INC (US) | 2008-04-23 | — | — | CN | disclosed |
| CN-101125864-A | Heteroaromatic inhibitor for fructose-1,6-bisphosphatase | METABASIS THERAPEUTICS INC (US) | 2008-02-20 | — | — | CN | disclosed |
| CN-100352505-C | Combination of FBP enzyme inhibitors and insulin sensitizers for the treatment of diabetes | METABASIS THERAPEUTICS INC (US) | 2007-12-05 | — | — | CN | disclosed |
| CN-100349904-C | Novel heteroaromatic inhibitors of fructose-1, 6-bisphosphatase | METABASIS THERAPEUTICS INC (US) | 2007-11-21 | — | — | CN | disclosed |
| CN-1900087-A | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase | METABASIS THERAPEUTICS INC (US) | 2007-01-24 | — | — | CN | disclosed |
| CN-1714866-A | A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes | METABASIS THERAPEUTICS INC (US) | 2006-01-04 | — | — | CN | disclosed |
| CN-1704423-A | Novel heteroaromatic inhibitors of fructose-1, 6-bisphosphatase | METABASIS THERAPEUTICS INC (US) | 2005-12-07 | — | — | CN | disclosed |
| CN-1215076-C | Novel heteroaromatic inhibitors of fructose-1, 6-bisphosphatase | METABASIS THERAPEUTICS INC (US) | 2005-08-17 | — | — | CN | disclosed |
| CN-1350466-A | Combination of FBP enzyme inhibitors and insulin sensitizers for the treatment of diabetes | METABASIS THERAPEUTICS INC (US) | 2002-05-22 | — | — | CN | disclosed |
| CN-1326459-A | Novel heteroaromatic inhibitors of fructose-1, 6-bisphosphatase | METABASIS THERAPEUTICS INC (US) | 2001-12-12 | — | — | CN | disclosed |
| US-4138432-A | Amides of phosphonoacetic acid | ABBOTT LABORATORIES (US) | 1979-02-06 | — | — | US | disclosed |
| US-4087522-A | Amides of phosphonoacetic acid for treating herpes simplex virus type 1 and 2 infections | ABBOTT LABORATORIES (US) | 1978-05-02 | — | — | US | disclosed |